Vimarsana
Biggest News Aggregation in the World

Flow Core News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Flow Core. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Flow Core Today - Breaking & Trending Today

New Sumida Surface Mount Power Inductors are constructed from Low-Loss Ferrite Core - Vimarsana News

New Sumida Surface Mount Power Inductors are constructed from Low-Loss Ferrite Core

High-Efficiency Power Inductors from New Yorker Electronics are Magnetically Shielded for Low Core Loss

Infant immune system beats the adult immune system at fighting off new pathogens - Vimarsana News

Infant immune system beats the adult immune system at fighting off new pathogens

As any parent knows, infants are prone to getting respiratory infections.

Infant immune systems are stronger than you think - Vimarsana News

Infant immune systems are stronger than you think

As any parent knows, infants are prone to getting respiratory infections. But a new study shows that the infant immune system is stronger than most people

The three pillar strategy to accelerating your success - Vimarsana News

The three pillar strategy to accelerating your success

A partner, not just a supplier. Three pillars to build a strategy to help you accelerate success

SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models - Vimarsana News

SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models

Science for just $15 USD. Short circuiting solid tumors Two major hurdles in chimeric antigen receptor (CAR) T cell therapy for solid tumors are ensuring specificity to tumor cells without affecting healthy cells and avoiding tumor escape due to antigen loss. To address these challenges, Hyrenius-Wittsten et al. and Choe et al. developed synthetic Notch (synNotch)–CAR T cells targeting solid tumor antigens and used them to treat mouse models of mesothelioma, ovarian cancer, and glioblastoma. In both studies, the authors demonstrated that synNotch-CAR T cells were better at controlling tum...